How to Explain Accretion/Dilution in Interviews

Twenty minutes into your superday, the banker across the table slides you a napkin math problem. A company trading at 20x earnings acquires one trading at 10x earnings, all stock. Is the deal accretive or dilutive?

You know the formula. You've drilled it, written it on a flashcard, even. But in the moment, you can't tell if the answer's supposed to be obvious, and you're not sure what the banker's actually looking for.

It's one of the most common technical questions you’ll encounter in M&A interviews. Most candidates fumble it the same way: they've got the formula down, but they can't tell you what it's actually measuring.

This guide aims to fix that. We will cover what accretion and dilution actually are, the formula and every adjustment that goes into it, the shortcut interviewers want to hear, how the answer changes with cash, debt, or stock, and exactly how to explain the logic clearly in an interview setting.

What Is Accretion/Dilution?

Accretion and dilution describe what happens to a buyer's earnings per share after it acquires another company.

Earnings per share is simply net income divided by the number of shares outstanding. After a deal closes, both of those numbers will change. The combined company may generate additional earnings from the target, but financing costs, interest expense, and purchase accounting adjustments can offset that benefit.

This is called pro forma earnings per share. Compare it to what the buyer would have earned standalone, and there's your answer: a higher pro forma EPS means accretive, a lower pro forma EPS means dilutive.

Bankers care about this metric for a few reasons. Public companies are required to report basic and diluted earnings per share every quarter, so shareholders are watching it closely. Management compensation is often linked to it as well; most importantly, it compresses a messy transaction into one number a board can react to in a meeting.

Running this analysis will tell you three things:

1. Whether the earnings you are buying cover what you are paying for them. A cheap target with steady earnings is easier to make accretive than an expensive one.
2. Whether your financing is expensive relative to those earnings, stock is a cheap currency when your multiple is high, and terrible currency when it is low.
3. How much synergy you would need to break even. If a deal is dilutive by ten cents, you can work backward to the cost savings required to close that gap.

One caveat matters more than anything else here, and it is where most candidates lose the question. Accretion and dilution are an earnings optics test, not a value test.

The Accretion/Dilution Formula and How to Calculate It

Every accretion/dilution calculation is a rebuild of one simple equation. Earnings per share is net income over shares outstanding, so a deal that changes either number changes the answer.

Work through it in seven steps:

1. Start with the buyer's standalone net income. This is your baseline: the earnings the company would have generated without the transaction.
2. Add the target's net income. You own their earnings now, so they add into the equation together.
3. Subtract interest on any new debt, after tax. Borrowing to make a purchase creates an expense that did not exist before.
4. Subtract any foregone interest income or investment return on the cash used to fund the acquisition. That cash was sitting somewhere earning a return. Spend it, and the return disappears.
5. Subtract new intangible amortization. Purchase accounting writes the target's assets up to fair value, and the identifiable intangible assets with finite useful lives, such as customer relationships or developed technology, now amortize against earnings.
6. Add expected synergies. Cost synergies are the adjustment most commonly modeled in interviews, though revenue synergies can help as well.
7. Divide by the pro forma share count. Take the buyer's existing shares and add any new shares issued to fund the deal.

Now, two key details that separate a clean answer from a sloppy one.

The first is the tax effect. Interest and amortization hit the income statement before taxes. That means the actual reduction in net income is smaller than how the raw number looks. Multiply each adjustment by one minus the tax rate, or you'll overstate your financing costs by roughly a third.

The second is the denominator. New shares only enter the picture when the buyer pays with stock. Compute them by dividing the stock portion of the purchase price by the buyer's share price.

An all-cash or all-debt deal leaves the share count unchanged, which can make accretion easier because the target's earnings are spread over the same number of shares. However, the interest cost of debt financing can still make a transaction dilutive.

Once both halves are rebuilt, the comparison is straightforward:

Accretion / (Dilution) % = (Pro Forma EPS ÷ Standalone EPS) − 1

A positive number means the deal is accretive and the buyer's earnings per share rise. A negative number means it is dilutive.

Most interviewers will not ask you to compute this to the decimal. They want to hear that you know which adjustments exist, which direction each one pushes, and why the share count matters as much as the earnings.

A Worked Example

A buyer trades at 20 times earnings. It posts $200 million of net income on 100 million shares, so earnings per share is $2.00 and the stock trades at $40.00.

The target trades at 10 times earnings, with $50 million of net income on 50 million shares. That puts its stock at $10.00 and its market value at $500 million.

The buyer then offers $13.00 per share, a 30% premium. That is a $650 million purchase price, or 13 times the target's earnings.

The financing is split three ways: 50% stock, 30% debt, 20% cash. The new debt costs 6%. The cash was earning 3%. The tax rate is 25%. Purchase accounting writes up $100 million of intangibles, amortized over ten years.

Standalone EPS: $2.00

Pro Forma Shares: 100.0M (existing) + (325M/40.00) = 108.1M

Pro Forma EPS: 230.8M/108.1M = $2.13

Accretion: +6.7%

The new shares come from the stock portion of the purchase price. $325 million divided by the $40.00 share price is 8.1 million shares. Add those to the buyer's existing 100 million, and the pro forma count is 108.1 million.

Divide $230.8 million by 108.1 million shares, and pro forma earnings per share are $2.13.

Against a standalone $2.00, that is 6.7% accretion.

Notice what drove it. The key driver is that the buyer is using stock valued at 20x earnings to acquire earnings that effectively cost 13x after the acquisition premium.

Because the buyer issues relatively few new shares for the amount of earnings acquired, the target contributes more earnings per share than the dilution created by the new stock issuance. Financing costs and amortization will drag on the result, but not nearly enough to flip the sign.

That relationship between the two multiples is the shortcut interviewers are often testing.

The Accretion/Dilution Rule of Thumb Interviewers Want to Hear

Interviewers don't want a full model on a whiteboard. They want to know you can see the answer before you even calculate it.

Here's the shortcut. In an all-stock deal, compare the buyer’s P/E multiple with the effective acquisition multiple paid for the target. If the buyer’s multiple is higher, the deal is generally accretive; if it is lower, the deal is generally dilutive.

But one small detail trips almost everyone up. It's not the target's trading multiple you're comparing against. It's what's actually being paid, premium included. 

The two companies from earlier traded at 10 times, but with the premium, the buyer paid 13. 20 against 13, so the deal is accretive because the buyer is using a more highly valued stock currency to acquire a lower-multiple earnings stream. Push that premium high enough that the offer reaches 22 times, and the same deal turns dilutive.

Most candidates stop there. The ones who get callbacks can explain why the rule actually works. 

Experienced analysts on the WSO forum frame it the same way, treating the deal as more of a spread between the acquired earnings yield and the buyer's currency costs.

A useful way to think about the rule is to convert both multiples into earnings yields by taking 1 ÷ P/E. A 20x multiple becomes a 5.0% earnings yield, while a 13x acquisition multiple becomes a 7.7% earnings yield.

So now the buyer is purchasing a 7.7% return and is paying 5% for the privilege. That positive spread is the core economic reason the deal tends to be accretive, although financing costs and other transaction adjustments can affect the final EPS result.

This framing is worth memorizing over the P/E rule itself. Multiples only compare cleanly in an all-stock deal, but every acquisition is the same trade underneath. You are buying an earnings stream and paying for it with something that has its own cost.

Cash, debt, stock; they're just three different price tags on the same purchase.

So when someone asks whether a 20x buyer acquiring a 10x target is accretive, don't just say yes. Name the premium, flip both sides into yields, and point out that the financing structure decides how much of that spread actually survives.

Why the Rule Breaks

The price-to-earnings shortcut works cleanly in precisely one situation: an all-stock deal with no other moving parts. Real transactions, however, are rarely that simple.

Cash changes the equation first. When a buyer pays cash, its own multiple never enters the calculation. What matters then is the interest that cash was earning before it left the balance sheet.

Cash generating 3% in a 25% tax environment costs the buyer 2.25% after tax. Set that against the earnings yielding 7.7%, and the deal is heavily accretive. That gap helps explain why all-cash deals are often accretive when the target's earnings yield exceeds the buyer's foregone after-tax return on cash.

Debt acts in the same way, just with a different rate. Borrow at 6% and the after-tax cost lands near 4.5%, still comfortably below a 7.7% yield.

The trade-off is that leverage increases. A deal can be accretive on day one and still leave the buyer with a more leveraged balance sheet that may concern lenders or credit-rating agencies.

Two adjustments transcend the rule entirely.

Purchase accounting marks the target's assets up to fair value, and that intangible amortization hits earnings every year going forward. No multiple comparison catches that.

Synergies move the other way; a deal that looks dilutive with the shortcut can turn accretive once cost savings get layered in. That is one reason acquirers place significant emphasis on synergy estimates in transaction announcements and investor presentations.

The rule also just breaks when the inputs are broken. Negative or near-zero target earnings? No meaningful multiple. Different tax jurisdictions? The comparison gets distorted too.

Use the shortcut to get a fast read. Then name the reasons it might be wrong. That's what interviewers actually notice.

How Financing Affects Accretion/Dilution: Cash, Debt, and Stock

The yield framing works as soon as you change how the deal is financed. Each structure has a cost associated with it, and when you compare that cost with the target's earnings yield, you can see whether the deal is likely to be accretive or dilutive.

All-cash. When a buyer pays with cash, the cost is the interest that the cash was earning before it left the balance sheet. Cash yielding 3% in a 25% tax environment costs 2.25% after tax.

Set that against a target yielding 7.7%, and the deal is then heavily accretive. This helps explain why cash-funded deals are often accretive when the target's earnings yield exceeds the buyer's foregone after-tax return on cash.

The share count will not move at all, because no new equity has been issued.

All-debt. Here, the cost is the after-tax interest rate due to the new borrowing. Debt at 6% in the same tax environment now costs 4.5% after tax, still comfortably below the 7.7% yield.

The trade-off here is leverage. Even though a debt-financed transaction might be accretive on the first day of close, the buyer's higher leverage may concern lenders and credit-rating agencies.

Like cash, debt will leave the share count untouched.

All-stock. Stock is the only item that touches the denominator. Its cost is the buyer's own earnings yield, and the flip of its price-to-earnings multiple. A buyer at 20 times earnings pays an effective 5%.

In this example, stock has the highest implied financing cost, and it is the only structure that increases the share count by issuing new equity. New shares will be issued, spreading the combined earnings across a wider count.

A useful insight follows from this: if a buyer's stock trades at a high multiple, that stock turns into cheap currency and stock transactions appear inexpensive. But when the multiple is low, the stock becomes expensive, and buyers prefer to use cash or debt.

Every deal is the same core trade. You are buying an earnings stream and choosing which price tag to attach to it.

Accretion/Dilution for Private Companies

All of our examples so far have been in a scenario where the target has a public market price with a visible multiple. In reality, however, many acquisitions aren’t quite like that. They’re private companies, which cuts off about half our shortcuts.

First, the target's multiple will go away. If a private company has no quoted price-to-earnings multiple, you cannot convert it into an earnings yield and compare it directly. You have to back out a multiple from the deal based on the negotiated sale price relative to the net earnings.

What hasn’t changed, however, is the buyer’s side of the equation. You still add the target's earnings, deduct the after-tax cost of the financing used for the transaction, and divide by the buyer's pro forma share count. Accretion and dilution are always calculated in terms of the buyer’s EPS, whether the target is public or not.

Financing tends to look a little different, too. The seller, often a founder or family, usually prefers to have the proceeds paid in cash, instead of equity in the buyer company. This leads those deals to be oriented towards either a cash sale or a debt structure.

Keep this one thought in mind. If no new shares are issued, the buyer's share count remains unchanged, which can make a cash- or debt-financed transaction more likely to be accretive.

The adjustment that gets larger is purchase price allocation. Private companies frequently carry assets on their books at old or understated values.

That write-up establishes noncash amortization, an earnings drain that persists for years. The intangible is typically larger in private transactions than in public ones, and the associated expense tends to be more volatile. Interviewers often expect candidates to raise this adjustment without being prompted.

So the takeaway is, the structure holds, but the target's missing multiple forces you to work from the deal price, and the accounting matters more than it does with a clean public comparison.

How to Answer Accretion/Dilution Questions in an Interview

Knowing the mechanics is one thing. Delivering a clean answer under pressure is another, and that is what the interview actually tests.

Expect at least one of these four questions in some form during your interview; they’re part of the broad finance interview questions you will face. Here's how to answer each.

A buyer at 20 times earnings acquires a target at 10 times, all stock. Accretive or dilutive? The classic: interviewers want the shortcut and the reason behind it.

1. Walk me through how you would determine whether a deal is accretive. This is a process question. Interviewers are checking whether you understand the key pro forma adjustments.
2. Why would a company pursue a dilutive acquisition? A judgment question, and the one that filters out most candidates.
3. What would make this deal accretive? They want to hear about price, financing mix, and synergies.
4. How does paying in cash instead of stock change the analysis? Now testing whether you understand the cost of consideration.

Answer all of them with the same four-step structure.

Start with the rule of thumb. Compare the buyer's multiple to the multiple being paid, and state which direction it points.

Then, name the financing. Cash, debt, and stock all carry different costs, and the structure decides how much of the spread survives.

Next, name the adjustments. New debt interest, foregone interest on cash, intangible amortization, synergies; all after tax.

Finally, close with a caveat. Accretion is an earnings test, not a value test, and a dilutive deal can still be the right deal.

Four common mistakes consistently hurt candidates in accretion/dilution interviews:

• Comparing against the target's trading multiple instead of the multiple actually being paid. The premium is what determines the answer.
• Forgetting that adjustments are done after tax. This overstates financing costs by roughly a third.
• Missing foregone interest on cash. Spending cash has an opportunity cost even when no new debt is raised.
• Treating dilutive as a synonym for bad. Plenty of value-creating deals have diluted earnings in year one.

The final point here holds the most weight. If an interviewer asks why a buyer would accept dilution, they're actually asking the candidate to present the benefits, long-term profit expansion, strategic positioning, and multiyear synergies that will emerge over time.

A candidate who treats every dilutive transaction as a bad decision is usually demonstrating an overly short-term view of value creation.

Sensitivity Analysis in an Accretion/Dilution Model

No banker walks into a room with one number. Purchase price moves during negotiation. Financing mixes get reworked. Synergy estimates are educated guesses nobody hits exactly. An accretion figure is only worth as much as the assumptions supporting it.

Instead, bankers build a sensitivity table that shows how accretion or dilution changes as two key assumptions move simultaneously.

The usual version puts offer price on one axis and stock consideration on the other. Every cell holds the accretion or dilution that combination produces.

These two assumptions usually have the largest immediate effect on pro forma EPS because they directly affect both the earnings acquired and the number of new shares issued.

Read the table from the earlier example and notice the pattern. In this example, stock is the most expensive financing currency, so moving right across any row and increasing the stock portion makes the deal less accretive.

Move down any column and the same thing happens for a different reason. The buyer is simply paying more for the same stream of earnings.

The cells that matter, however, are the ones where the sign flips. Above that boundary, the deal adds to earnings per share. Below it, the deal starts costing the buyer.

At $19.00 per share and 50% stock, the deal is barely positive at 0.7%. Push the stock portion to 75%, and it becomes dilutive. That breakeven boundary is often the most important takeaway for bankers during transaction negotiations.

You can check out WSO's free Accretion Calculation template and Dilution Calculation template resources to pressure-test this concept yourself.

The practical use is straightforward: management wants to know how much room it has before a transaction becomes dilutive. A sensitivity table answers that question on a single page and turns a modeling exercise into a practical negotiating framework.

Interviewers sometimes ask which variables you'd sensitize. Usually it's the pair we just covered: purchase price and consideration mix. Synergy realization and interest rates on new debt come up too, and WSO’s financial modeling course walks through how that's built in practice.

Whichever pair you choose, the point is the same. You are showing where the deal breaks, not just where it stands today.

Free Resources

To continue learning and advancing your career, check out these additional helpful WSO resources:

• Advanced Financial Modeling (AFM)
• Financial Modeling Best Practices
• What Makes a Good Financial Model?
• Top Financial Modeling Courses
• Valuation Modeling in Excel